Search Result

Results for "

MEK inhibitor1

" in MedChemExpress (MCE) Product Catalog:

標的別:	MEK (11) Apoptosis (1) Autophagy (2) ERK (2) Influenza Virus (2) Mitophagy (2) PARP (1) Reference Standards (1)
研究分野別:	Cancer (13)

阻害剤およびアゴニスト

蛍光色素

生化学アッセイ試薬

ペプチド

Targets Recommended: PAI-1 MEK ASK1

製品番号	製品名	Target	研究分野	構造式

HY-12031A

U0126 Maximum Cited Publications 459 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-12031

U0126-EtOH Maximum Cited Publications 459 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-15610

GDC-0623 5+ Cited Publications RG 7421; MEK inhibitor 1	MEK Apoptosis	Cancer
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAF ^V600E, EC₅₀=7 nM).

HY-147245

Basroparib STP1002	PARP	Cancer
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC₅₀ of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC₅₀ of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor .

HY-10254G

Mirdametinib 1 Publications Verification PD0325901; PD325901	MEK	Cancer
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

HY-139638

**MEK4 inhibitor-1**	MEK	Cancer
MEK4 inhibitor-1 is a novel *MEK4* inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

HY-146127

*Grb2 SH2 domain inhibitor* 1**	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of *p-MEK. Grb2 SH2 domain inhibitor 1* can be used in the research of breast cancer .

HY-P4133

**MEK1 Derived Peptide Inhibitor 1**	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P4136

Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM .

HY-12042A

Pimasertib hydrochloride AS703026 hydrochloride; MSC1936369B hydrochloride	MEK	Cancer
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor .

HY-107619

PD-334581	MEK	Cancer
PD-334581 is a *MEK1* inhibitor .

HY-107619R

PD-334581 (Standard)	Reference Standards MEK	Cancer
PD-334581 (Standard) is the analytical standard of PD-334581 (HY-107619). This product is intended for research and analytical applications. PD-334581 is a MEK1 inhibitor .

製品番号	製品名	Type

HY-10254G

Mirdametinib 1 Publications Verification PD0325901; PD325901	蛍光色素
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

製品番号	製品名	Type

HY-10254G

Mirdametinib 1 Publications Verification PD0325901; PD325901	生化学アッセイ試薬
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

製品番号	製品名	Target	研究分野

HY-146127

*Grb2 SH2 domain inhibitor* 1**	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of *p-MEK. Grb2 SH2 domain inhibitor 1* can be used in the research of breast cancer .

HY-P4133

**MEK1 Derived Peptide Inhibitor 1**	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P4136

Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

お名前
メール *

	Sorry, but the email address you supplied was invalid.